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Objective. We sought to determine whether racial disparities in tumor characteristics among uterine
cancer patients persisted, and varied by age, in an equal-access healthcare population.
Methods. The distributions of tumor histology, stage and grade by race were compared for uterine cancers
diagnosed from 1990 to 2003 using data from the U.S. Department of Defense's Automated Central Tumor
Registry. Comparisons were conducted overall and stratified by age (b50, ≥50) using the Chi-square test.
Results. Of 2582 uterine tumors identified, 2057 (79.7%) were diagnosed among White women and 183
(7.1%) among Black women. Among all women analyzed, Blacks were more likely than Whites to present with
non-endometrioid tumors (47.7% vs 23.5%, pb0.01), non-localized tumors (31.8% vs 24.5%, p=0.02), and poorly
differentiated tumors (20.5% vs 15.0%, pb0.01). Among women 50 years and older, similar significant racial
disparitieswereobserved.However, no significant racial differenceswere observed amongyoungpatients.When
comparisons were restricted to endometrioid histology adenocarcinomas, trends in age-specific disparities for
older women were observed.
Conclusions. Our study suggests that racial disparities in uterine cancers persist between Blacks and Whites
in an equal-access population. Blacks endure higher stage and grade tumors, and more aggressive histologies. This
disparity in clinicopathologic factors is confined to women older than 50 years. Multiple factors such as racial
variation in age-related health knowledge/behavior and estrogenmetabolismmay be related to the racial disparity.
Published by Elsevier Inc.
Introduction
Uterine corpus cancer is the most common gynecologic malignancy
in the United States, accounting for approximately 6% of all tumors
diagnosed [1]. The vast majority of these tumors arise from the
endometrium. The American Cancer Society estimated that 43,470
new cases of and 7950 deaths from endometrial cancer would occur
during 2010 [1]. While uterine cancer incidence rates are lower among
Black women than White women, [2] Blacks are more often diagnosed
with aggressive histologic subtypes, advanced tumor stages, and/or
higher tumor grades, and they suffer a correspondinglyworse prognosis
[2–21]. Indeed, the disease-specific mortality rate for Black women is
nearly double that endured by White women [2].
The etiology of the observed survival disparities between Black and
White women likely is multi-factorial [5–7,10,12,13,15–17,20–27].
One of the often-cited explanations is racial variation in access to care
[5–7,12,13,22,23]. With decreased access, Black women may see
physicians less often or delay in seeking care, and thereby they may
present at later stages orwithmore aggressive histologies [6,7,10,12,13,
22,23,28,29]. Treatment differences, including inconsistencies in pri-
mary and adjuvant therapies, have also been implicated in the
disparities in outcome and survival [7,9,12,13,15,17,22,23,26]. Multiple
studies have evaluated contributions of various socioeconomic factors
to endometrial cancer disparities, yet often theyhave beenhamperedby
an inability to adequately control for confounding variables. Elucidation
and clarification of any clinicopathologic disparities between Blacks
and Whites could provide improved individualized treatments for
endometrial cancer patients. The Department of Defense's (DoD)
Military Health System provides a unique setting to investigate racial
disparities because equal healthcare access is provided regardless of age,
race, gender, or socioeconomic status [30].
Kost, et al. [30] previously evaluated clinicopathologic factors of
endometrial cancer by race among DoD beneficiaries and found that
Gynecologic Oncology 123 (2011) 76–81
☆ The views expressed in this article are those of the authors and do not necessarily
reflect the official policy or opinion of the Department of Defense or the United States
Army or Navy, nor the US Government.
⁎ Corresponding author.
E-mail address: john.farley@us.army.mil (J.H. Farley).
0090-8258/$ – see front matter. Published by Elsevier Inc.
doi:10.1016/j.ygyno.2011.06.027
Contents lists available at ScienceDirect
Gynecologic Oncology
j ourna l homepage: www.e lsev ie r.com/ locate /ygyno
White women presented with more favorable tumor stage, grade,
and histologic types. The objective of the current study was to assess
whether these previously described disparities between White and
Black DoD beneficiaries persisted using the DoD-wide cancer registry
data and whether the racial differences varied by age.
Materials and methods
After obtaining Institutional Review Board approval, uterine cancer
data among DoD beneficiaries were extracted from the Automated
Central Tumor Registry (ACTUR). Originating in 1986, ACTUR collects and
tracks cancer data for DoD beneficiaries diagnosed or treated at military
treatment facilities, including active-duty military personnel, retirees,
and their dependents. Local tumor registrars, in direct consultation
with corresponding gynecologic oncologists, abstract and enter data from
a newly-diagnosed cancer patient's pertinent clinical history. Details
regarding the tumor (e.g., site, histology and stage) and the patient (e.g.,
gender, race and age at diagnosis) then are forwarded for inclusion in the
ACTUR database.
Clinical and pathologic data were extracted for all patients with
invasive endometrial cancer included in the ACTUR database between
1990 and 2003. While all submitted data undergo verification, data
prior to 1990 were excluded to minimize potential incomplete
recording during the initial years of the cancer registry. Previously
described methods [31] developed using national and state cancer
registry guidelines [32,33] were employed to identify and consolidate
duplicate records. Abstracted variables included race, age at diagnosis,
histology, grade, and stage. Patients were classified into groups: by
age (b50 years or≥50 years), and by race. Agewas used as a proxy for
menopausal/hormonal status. Various age thresholds for menopause
have previously been employed in the literature. We selected a
threshold of age 50 years in accordance with an investigation which
revealed that, above this threshold, age-specific survival in endome-
trial cancer decreased significantly [34]. Race was determined by the
primary gynecologic oncologist at the time of diagnosis or treatment
using observation or beneficiary health record data, and was recorded
in the respective local tumor registry.
Cases were categorized using the appropriate edition of the
International Classification of Diseases for Oncology (ICD-O) [35–37].
The previous versions of ICD-O codes were converted to the third
edition (ICD-O-3) by applying established guidelines. Uterine corpus
cancers were defined using the primary site (topography) codes C540–
C543, C548–C549 and C559. Histology was defined using the ICD-O-3
morphology codes and classified as endometrioid [8380 (endometrioid
adenocarcinoma), 8382 (endometrioid adenocarcinoma secretory
variant), 8383 (endometrioid adenocarcinoma ciliary cell variant),
8140 (adenocarcinoma NOS)], non-endometrioid (all other known
morphology), and unknown (9999). Central pathologic review of
pathologic specimens was not performed.
Tumorswere graded by extent of differentiation: well, moderately,
poorly, undifferentiated, or unknown. One ambiguous case was
excluded secondary to having a tumor grade designated as “B-cell,”
which suggested a non-uterine primary. Stage was categorized as local,
regional, distant or unknown by combining Surveillance, Epidemiology
and End Results (SEER) Summary Stage variables. Racial differences in
the tumor characteristicswere assessed using the Chi-square or Fisher's
exact test for small sample sizes. The significance level was specified as
pb0.05. All calculations were performed using SAS Statistical Software,
version 9.1 (SAS Institute, Inc., Cary, NC).
Results
Query of the ACTUR database revealed a total of 2582 eligible
uterine tumors. There were 1924 (74.5%) tumors of endometrioid
histology and 655 (25.4%) tumors of non-endometrioid histologic
subtype, even though a central pathologic review and confirmation of
histologic characteristics were not performed [Table 1]. Only 3 cases
were designated as having unknown histology [Table 1]. Abstracted
race designations included White, Black, Other, and Unknown. We
restricted our analysis to the two racial categories which were
specified discretely (White and Black). Of the 2582 tumors abstracted,
2057 (79.7%) were diagnosed among White women and 183 (7.1%)
were diagnosed among Blacks [Table 1]. Forty-six tumors occurred in
women on active duty, while the remaining tumorswere diagnosed in
retirees, dependents and family members [Table 1]. Given the small
numbers of tumors in active duty women, we restricted our analysis
to comparisons involving the non-active duty beneficiary population.
Of the 2536 tumors in non-active duty beneficiaries, 2022 (79.7%)
were identified in White women and 176 (6.9%) were identified in
Blacks [Table 1].
Mean age at diagnosis in each of the age categories was similar for
both Blacks and Whites. For young women (b50 years), the mean age
at diagnosis was 42.1 years for Whites and 40.8 years for Blacks
(p=0.23), while for older women (≥50 years), the mean ages at
diagnosis were 63.6 years and 63.0 years for Whites and Blacks,
respectively (p=0.43) [Table 2]. Similar results were noted when
restricting the analysis to endometrioid histology [Table 2]. Not
surprisingly, statistically significant distributions toward lower stage
and grade favoring endometrioid histology were observed irrespec-
tive of age stratification (data not shown).
More Black women than White women were predisposed to non-
endometrioid histology, (47.7% vs 23.5%, pb0.01) [Table 3]. This
relationship persisted when evaluating the older age group, with
more Blacks than Whites older than 50 years presenting with non-
Table 1
Racial comparison of uterine cancer by tumor histology and duty status at diagnosis among all Department of Defense healthcare beneficiaries, Automated Central Tumor Registry
1990–2003.
Duty status Histology White Black Other Unknown Total
N % N % N % N % N %
Active duty Endometrioid 26 74.3 6 85.7 2 100.0 0 0.0 34 73.9
Non-endometrioid 9 25.7 1 14.3 0 0.0 2 100.0 12 26.1
Unknown 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total 35 7 2 2 46
Non-active duty Endometrioid 1545 76.4 92 52.3 197 74.1 56 77.8 1890 74.5
Non-endometrioid 475 23.5 84 47.7 69 25.9 15 20.8 643 25.4
Unknown 2a 0.1 0 0.0 0 0.0 1 1.4 3a 0.1
Total 2022 176 266 72 2536
All beneficiaries Endometrioid 1571 76.4 98 53.6 199 74.3 56 75.7 1924 74.5
Non-endometrioid 484 23.5 85 46.4 69 25.7 17 23.0 655 25.4
Unknown 2a 0.1 0 0.0 0 0.0 1 1.4 3a 0.1
Total 2057 183 268 74 2582
a One case was excluded secondary to B-cell histology suggesting a non-uterine primary.
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endometrioid histology (50% vs 22.7%, respectively, pb0.01) [Table 3]. No
such pattern was observed in young women [Table 3].
With respect to stage at diagnosis, more Whites than Blacks
presented with localized disease (75.6% vs 68.2%, p=0.02) [Table 3].
For women at least 50 years old, more White women were diagnosed
with localized disease compared with Black women (75.1% vs 65.7%,
pb0.01), while no racial differences in stage at diagnosis were noted in
young women [Table 3]. Similar results were observed when consid-
ering grade at diagnosis. White women, in general, more often
presented with well-differentiated tumors (45.2% vs 34.7%, pb0.01)
[Table 3]. No significant racial variations between young White and
Black women were observed, yet Whites were more likely to be
diagnosed with well-differentiated tumors than Blacks (43.8% vs 29.3%,
pb0.01) when women older than 50 years were evaluated [Table 3].
When comparisonswere restricted to endometrioid histology, although
there was a tendency forWhitewomen to havemore favorable tumors,
none of the racial differences were significant [Table 4]. However,
among older women, the racial difference in tumor grade was
borderline significant with more Blacks than Whites diagnosed with
poorly differentiated tumors (20.0% vs 12.9%, p=0.06) [Table 4].
Discussion
This study confirms that the often-cited racial disparity in clinicopath-
ologic characteristics between Blacks andWhites [2–21] remains evident
despite equal access to care. Moreover, we demonstrate that this racial
variation is confined to older women, with Blacks prejudicially enduring
non-endometrioid, non-localized, and poorly differentiated tumors.
The data may suggest similar trends when considering endometrioid
histologies alone.
Other investigators have attempted to evaluate the effect of
socioeconomics on racial disparities. Hill, et al. [10] reported an
analysis of data from the Black/White Cancer Survival Study (BWCSS).
This study found that poverty index influenced grade at diagnosis. Yet,
it necessarily was hampered by the drawbacks associated with any
population-based evaluation, [38] as well as by selection biases arising
both from exclusion of cases with incomplete interview records and
from failure to capture grossly underserved patients. Barrett, et al. [6]
also evaluated a cohort from the BWCSS; those results likewise were
affected by the disadvantages hindering Hill, et al. [10]. Kost, et al. [30]
evaluated an analogous DoD beneficiary population; however, our
investigation expanded on both the population and goals considered
in that study.
Table 2
Observed age comparisons by age group and by race among non-active duty
Department of Defense healthcare beneficiaries, Automated Central Tumor Registry,
1990–2003.
White Black
Histology Age N Mean Stda N Mean Stda p-valueb
All b50 370 42.1 0.32 36 40.8 1.20 0.23
≥50 1652 63.6 0.20 140 63.0 0.67 0.43
Endometrioid b50 270 42.9 0.34 22 40.8 1.43 0.10
≥50 1275 63.3 0.23 70 63.4 0.84 0.94
a Std Dev = standard deviation.
b Reported p-value from t-test.
Table 3
Racial comparison of uterine cancer by age, tumor histology, stage and grade at diagnosis
among non-active duty Department of Defense healthcare beneficiaries, Automated
Central Tumor Registry 1990–2003.
Age at
diagnosis
Tumor characteristic White Black p valuea
All Histology Endometrioid 1545 76.4% 92 52.3% b0.01
Non-endometrioid 475 23.5% 84 47.7%
Unknown 2 0.1% 0 0.0%
Stage Local 1,528 75.6% 120 68.2% 0.02
Regional 256 12.7% 24 13.6%
Distant 113 5.6% 20 11.4%
Unknown 125 6.2% 12 6.8%
Grade Well differentiated 913 45.2% 61 34.7% b0.01
Moderately
differentiated
518 25.6% 31 17.6%
Poorly
differentiated
304 15.0% 36 20.5%
Undifferentiated 17 0.8% 2 1.1%
Unknown 270 13.4% 46 26.1%
b50 Histology Endometrioid 270 73.0% 22 61.1% 0.13
Non-endometrioid 100 27.0% 14 38.9%
Unknown 0 0.0% 0 0.0%
Stage Local 288 77.8% 28 77.8% 0.95
Regional 44 11.9% 5 13.9%
Distant 17 4.6% 1 2.8%
Unknown 21 5.7% 2 5.6%
Grade Well differentiated 189 51.1% 20 55.6% 0.14
Moderately
differentiated
84 22.7% 3 8.3%
Poorly
differentiated
42 11.4% 6 16.7%
Undifferentiated 3 0.8% 1 2.8%
Unknown 52 14.1% 6 16.7%
≥50 Histology Endometrioid 1275 77.2% 70 50.0% b0.01
Non-endometrioid 375 22.7% 70 50.0%
Unknown 2 0.1% 0 0.0%
Stage Local 1,240 75.1% 92 65.7% b0.01
Regional 212 12.8% 19 13.6%
Distant 96 5.8% 19 13.6%
Unknown 104 6.3% 10 7.1%
Grade Well differentiated 724 43.8% 41 29.3% b0.01
Moderately
differentiated
434 26.3% 28 20.0%
Poorly
differentiated
262 15.9% 30 21.4%
Undifferentiated 14 0.8% 1 0.7%
Unknown 218 13.2% 40 28.6%
a Chi-square or Fisher's exact p-value in comparison to Whites.
Table 4
Racial comparison of endometrioid histology by age, stage and grade at diagnosis
among non-active duty Department of Defense healthcare beneficiaries, Automated
Central Tumor Registry 1990–2003.
Age at
diagnosis
Tumor characteristic White Black p-valuea
All Stage Local 1,211 78.4% 67 72.8% 0.20
Regional 181 11.7% 10 10.9%
Distant 57 3.7% 7 7.6%
Unknown 96 6.2% 8 8.7%
Grade Well differentiated 792 51.3% 45 48.9% 0.17
Moderately
differentiated
435 28.2% 19 20.7%
Poorly differentiated 192 12.4% 17 18.5%
Undifferentiated 4 0.3% 0 0.0%
Unknown 122 7.9% 11 12.0%
b50 Stage Local 224 83.0% 16 72.7% 0.34
Regional 27 10.0% 3 13.6%
Distant 6 2.2% 1 4.5%
Unknown 13 4.8% 2 9.1%
Grade Well differentiated 155 57.4% 17 77.3% 0.22
Moderately
differentiated
68 25.2% 2 9.1%
Poorly differentiated 28 10.4% 3 13.6%
Undifferentiated 1 0.4% 0 0.0%
Unknown 18 6.7% 0 0.0%
≥50 Stage Local 987 77.4% 51 72.9% 0.23
Regional 154 12.1% 7 10.0%
Distant 51 4.0% 6 8.6%
Unknown 83 6.5% 6 8.6%
Grade Well differentiated 637 50.0% 28 40.0% 0.06
Moderately
differentiated
367 28.8% 17 24.3%
Poorly differentiated 164 12.9% 14 20.0%
Undifferentiated 3 0.2% 0 0.0%
Unknown 104 8.2% 11 15.7%
a Chi-square or Fisher's exact p-value in comparison to Whites.
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Liu, et al. [12] addressed delay in presentation to care, finding no
significant difference in time to presentation following the onset of
vaginal bleeding between Blacks and Whites, yet simultaneously
demonstrating persistent racial disparities in histology, stage and
grade burdening Black women. While these results are provocative,
the study included several drawbacks. In addition to involving only a
small number (thirty-nine) of Black patients, the results were
influenced by an undisclosed number of excluded patients who
underwent radiation therapy alone due to severe medical conditions.
This potentially introduced bias as Black patients have been shown to
be disproportionately affected by poor overall health status [39].
Furthermore, while the investigation evaluated all patients meeting
inclusion criteria at their institution, it made no comment regarding
the uniformity of access to care for the hospital's catchment area.
The prognostic significance of age in endometrial cancer has been
established previously, although the critical age is debatable [3,5,9,11,
16,20,34,40]. Our stratification used 50 years old as a surrogate for
menopausal status, based upon prior demonstration of a significant
decrease in endometrial cancer survival after that threshold [34]. Thus,
our results suggest that racial disparities in endometrial cancers are
confined to postmenopausal Blacks when compared to Whites, and no
such relationship exists for premenopausal women. Furthermore, when
we excluded non-endometrioid histologies, a similar trend emerged,
implying that the observed disparities may not be exclusively due to the
preponderance of high-risk tumors in Blacks. This association with
menopausal status may suggest variable estrogen exposure between
racial groups, a mechanism that is particularly relevant in the absence of
an intact hypothalamic–pituitary–ovarian axis.
The endometrium is hormonally sensitive, so it is not surprising
that alterations in the hormonal milieu may contribute to carcino-
genesis. The majority of endometrial cancers are diagnosed in the
setting of estrogen excess in patients with risk factors for either
unopposed endogenous or exogenous estrogen exposure. Tumors arising
in this milieu are predominantly type I, or of endometrioid subtype
[40,41]. Type II tumors, in contrast, are less common, demonstrate worse
differentiation, andportenda less favorableprognosis [40,41]. Typically of
uterine papillary serous or clear cell histologic subtype, type II tumors are
thought to develop independent of estrogen exposure, arising instead in
the setting of an atrophic endometrium [40,41]. Dedifferentiation from
type I to type II may also occur [29].
Differential estrogen metabolism has long been implicated in
developmentof hormonally-sensitive cancers [5,6,10,16,41–43].Within
the endometrium, estrogen induces transcriptional changes that cause
downstream promotion of cell proliferation and inhibition of apoptosis
[43–45]. In addition, depurinating adducts from estrogen's oxidative
metabolites are believed to be carcinogenic [43]. Alterations in estrogen
metabolism also have been implicated in oncogenesis through gene
polymorphisms [42,45,46]. The cytochrome p450 enzyme CYP1B1, for
example, has been linked to breast cancer development [45,47]. CYP1B1
upregulation is thought to instigate cellular damage by catalyzing the
hydroxylation of estrogens, and it can disrupt cellular proliferation
through interference with cell cycle regulation [29,45]. Polymorphisms
of the CYP1B1 codons result in hyperactivation, and have been shown to
impart increased incidence in endometrial cancer, [45,46] though the
findings have been conflicting [42,46]. In a separate pathway, estrogens
bind to the estrogen receptor ligand binding domain, resulting in
stimulation of cell proliferation in these target tissues [46]. Poly-
morphisms of estrogen receptor alpha likewise have been implicated in
conferring increased risk of endometrial cancers in a recent pilot study
by Sliwinski, et al [46]. Concurrent investigation into the seven-
transmembrane estrogen receptor GPR30, whose activation is known
to promote endometrial proliferation, has highlighted a potential novel
pathway for estrogen-mediated endometrial carcinogenesis [44].
Estrogen metabolism is an obvious focus for investigation into the
etiology of the observed racial disparities in endometrial cancer. Indeed,
racial variations in exogenous hormone use previously have been
identified as contributors to differences in outcome between Blacks and
Whites [10,16,42]. While unopposed exogenous estrogen serves as a
risk factor for endometrial cancer development, the resulting tumors are
typically of the more favorable type I biology and therefore are
associated with better prognosis [10,40–42]. Estrogen replacement
more often is prescribed to Whites than Blacks, in part perhaps,
contributing to higher rates of type I tumors among Whites [6,42].
However, when controlling for exogenous hormone use, the observed
disparities in rates of type I tumors remain, suggesting that other aspects
of tumor biology also must be implicated [16]. Endogenous estrogen
exposure has also been cited. Direct associations between themetabolic
syndrome and its individual components and endometrial cancer risk
have been previously described [48]. Brancati, et al. [39] reported that
Blacks suffer a two-fold increased risk of diabetes when compared with
Whites, even when controlling for the usual surrogates for obesity, BMI
and waist-to-hip ratio. Related factors may account for the excess
endometrial cancer risk we demonstrated in postmenopausal Black
women.
The role of estrogen in racial disparities was highlighted in a
retrospective analysis of Gynecologic Oncology Group (GOG) 137 data
comparing recurrence-free and overall survival between Whites and
Blacks receiving post-operative estrogen replacement therapy for
surgically treated, early-stage endometrial cancer [16] .While the Blacks
on the treatment arm endured a relative risk of recurrence of 11.2when
compared with Whites, a similar relationship was not observed for the
Blacks on the placebo arm [16]. The study concluded that Blacksmay be
at increased risk of recurrence when maintaining post-operative
estrogen therapy and suggested that potential differences in estrogen
metabolism could be a source of the racial variation [16].
Molecular alterations may contribute to differences in outcome
between Blacks andWhiteswith endometrial cancer. An analysis of 147
patients diagnosed with endometrial cancer between 1995 and 2001
sought to analyze and compare the molecular profiles in endometrial
cancer inWhite and Black patients using a number of knownmolecular
markers [18]. Black patients had more type II carcinoma than White
patientswithhighp53protein expression increased significantly among
the Black patients (49% vs. 30%, P=0.035) versus White patients [18].
Studies have shown that p53 over-expression in endometrial cancer is
associated with a more aggressive tumor characteristics and behavior
including poor differentiation, deep myometrial invasion and lymph
node metastases [15–18].
In another study 140 stage III/IV endometrial adenocarcinomaswere
screened formutations in the PTEN gene [14]. Blackwomenhad cancers
with significantly higher stage and grade that were more often
nonendometrioid. PTEN mutation was seen in 14% cancers and was
associated with endometrioid histology and more favorable survival.
The frequency of PTEN mutations was significantly higher in Whites
(22% vs 5%, P=0.006) [14]. This suggests that differences in the
frequency of PTEN mutations contribute to the racial disparity in
endometrial cancer survival.
One limitation of our study is the lack of uniformity in race reporting
within the ACTUR database. While the primary gynecologic oncologist
establishes the race designation forwarded to the registry, this pro-
vider typically ascertains the patient's race using the DoD's electronic
beneficiary health record database. Race determination in this system
is made upon enrollment as a military beneficiary, and arises from a
combination of self- and administrative reporting. The balance of racial
categories in ACTUR is determined through physician-reporting. As these
racedesignations areunconfirmed, theymay lead tomisclassification that
could attenuate the differences we reported between Blacks andWhites.
Such attenuation could mask true differences in younger women or
underestimate the differences observed in older women. Furthermore,
the heterogeneous distribution of military treatment facilities may
introduce selection bias in the patients reported to ACTUR, as remote
patients are often referred for care in the civilian sector and therefore are
not captured. This bias affects retired personnel and their dependents
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more significantly than active dutymembers. Given the small numbers of
White [35] and Black [7] active duty patients, we focused on non-active
duty beneficiaries and potentially introduced another source of bias.
Finally central pathologic review of all tissue and surgical specimens
was not performed in this retrospective database review. This may bias
those patients treated at academic centers, historically White patients,
where specialized pathologists were available. Specialized pathologic
review should allow more accurate diagnosis of advanced grade and
poor prognosis histologic specimens. All patients included in this study
were initially treated at medical centers with specialized pathologic
review. Also, even among experts, reproducibility of endometrial cancer
pathologic diagnosis can be suspect [10,49]. Evaluations of low grade
and atypical hyperplastic lesions of the endometrium are notoriously
poor [10,49]. Additionally, although FIGO grading has significant
predictive value, the reproducibility of Grade 2 is limited such that a
binary grading system has been proposed. Even with the binary system
reproducibility among pathologists is poor and varies from only 80% to
85% [49].
Our study confirms that racial disparities in uterine cancers persist
between Blacks and Whites in an equal access to care environment,
suggesting that a significant proportion of the observed disparities
cannot be attributed solely to unequal access to care. Furthermore, we
found that older Black women carried the burden of the disparate
tumor characteristics. Similar trends observed when considering
endometrioid histology alone suggest that the disparities cannot be
entirely attributed to racial differences histology. Further investiga-
tion into the nature of endometrial cancer disparity is warranted,
particularly in order to confirm these results in other populations for
which confounding factors (such as socioeconomics and access to
care) are adequately controlled.
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